Providence Medical Technology receives $10.5M new equity financing — 5 points

Written by Megan Wood | December 19, 2016 | Print  |

Walnut Creek, Calif.-based Providence Medical Technology closed a new equity financing round of $10.5 million.

Here are five points:


1. The company plans to use the funding to boost the commercialization of its cervical fusion technology portfolio.


2. London, U.K.-based MVM Life Science Partners, a new investor, led the financing. The company is now a part of Providence's board of directors.


3. Jupiter, Fla.-based Stanmore Medical Investments and Mill Valley, Calif.-based Aphelion Capital also participated in the financing round.


4. Providence develops tissue-sparing, cervical fusion technology.  


5. The company is currently working on commercializing the DTRAX platform of single-use, tissue-sparing instruments and CAVUX implants for cervical fusion.


More articles on devices:
Zimmer Biomet's growth strategy in spine: MIS, cervical and becoming a 'health solutions provider'
Predictive Technology Group highlights US patent allowance for treating patients with genetic spinal deformities, syndromes: 5 highlights
Global wearable medical devices market to hit $12.1B by 2021: 9 observations

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months